Shots:

• Aspen to receive $330.68M up front along with up to $110.22M deferred consideration upon fulfillment of certain conditions- making a total deal value ~$440.9M. The transaction is anticipated to be closed in H1’20
• The acquisition will complement Sandoz’s hospital generic and biosimilar portfolio- further expand its access to the hospital channel in Japan and allow Sandoz to bolster its position in the world’s third-largest generics market
• Additionally- the companies sign a manufacturing and supply agreement (with an additional two-year extension option) for 5yrs. Aspen’s portfolio in Japan consists of ~20 products- off-patent medicines focusing on anesthetics (including Xylocaine)- specialty brands (including Imuran) and local brands

Click here to­ read full press release/ article | Ref: Novartis  | Image: Aspen Group Site